DK1556080T3 - Furin-inhibitorer til anvendelse af fibrose og ardannelse - Google Patents

Furin-inhibitorer til anvendelse af fibrose og ardannelse

Info

Publication number
DK1556080T3
DK1556080T3 DK03765179.1T DK03765179T DK1556080T3 DK 1556080 T3 DK1556080 T3 DK 1556080T3 DK 03765179 T DK03765179 T DK 03765179T DK 1556080 T3 DK1556080 T3 DK 1556080T3
Authority
DK
Denmark
Prior art keywords
scarring
fibrosis
furin inhibitors
inhibitors
furin
Prior art date
Application number
DK03765179.1T
Other languages
English (en)
Inventor
Mark W J Ferguson
G Brunner
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of DK1556080T3 publication Critical patent/DK1556080T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK03765179.1T 2002-07-24 2003-07-23 Furin-inhibitorer til anvendelse af fibrose og ardannelse DK1556080T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0217136.1A GB0217136D0 (en) 2002-07-24 2002-07-24 Wound healing & treatment of fibrosis
PCT/GB2003/003159 WO2004009113A1 (en) 2002-07-24 2003-07-23 Use of convertase inhibitors in the treatment of fibrosis and scarring

Publications (1)

Publication Number Publication Date
DK1556080T3 true DK1556080T3 (da) 2011-01-31

Family

ID=9941004

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03765179.1T DK1556080T3 (da) 2002-07-24 2003-07-23 Furin-inhibitorer til anvendelse af fibrose og ardannelse

Country Status (11)

Country Link
US (2) US7700562B2 (da)
EP (1) EP1556080B1 (da)
JP (1) JP4630661B2 (da)
AT (1) ATE486609T1 (da)
AU (1) AU2003254473B2 (da)
CA (1) CA2492331A1 (da)
DE (1) DE60334830D1 (da)
DK (1) DK1556080T3 (da)
ES (1) ES2355094T3 (da)
GB (1) GB0217136D0 (da)
WO (1) WO2004009113A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025611A1 (en) * 2003-09-16 2005-03-24 Pharmacia Corporation Inhibitors of pace4 for the treatment of arthritis
WO2005037150A1 (en) * 2003-10-16 2005-04-28 Osteotech, Inc. System and method for flexible correction of bony motion segment
WO2008066707A2 (en) * 2006-11-29 2008-06-05 Dana-Farber Cancer Institute Targeting prohormone convertase enzymes to suppress pomc-msh processing to induce skin lightening
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
WO2010003231A1 (en) * 2008-07-11 2010-01-14 Socpra-Sciences Et Génie S.E.C. Multi-leu peptides and analogues thereof as selective pace4 inhibitors and effective antiproliferative agents
WO2012076985A2 (en) * 2010-12-06 2012-06-14 The University Of British Columbia Granzyme b inhibitor compositions, methods and uses for promoting wound healing
JP6472608B2 (ja) 2014-05-21 2019-02-20 ソマール株式会社 Ｎ−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム
WO2017141032A1 (en) * 2016-02-15 2017-08-24 Oxford University Innovation Limited Treatment of fibrotic disorders
FR3110345B1 (fr) 2020-05-21 2024-03-29 Agence Francaise Pour Le Dev D’Al Ula Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356595A1 (en) 1988-09-01 1990-03-07 Merrell Dow Pharmaceuticals Inc. Novel peptidase inhibitors
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5439824A (en) * 1993-05-06 1995-08-08 The United States Of America Increased expression of α-1-antitrypsin in expression vectors through the inclusion of intron II
GB9314350D0 (en) 1993-07-12 1993-08-25 Zeneca Ltd Armide derivatives
EP0968723B1 (en) 1994-03-29 2009-07-01 Renovo Limited Healing of wounds or fibrotic disorders using at least one agent against a growth factor
GB2324960A (en) 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
AU771635B2 (en) * 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6262020B1 (en) * 2000-02-15 2001-07-17 Alphamed Pharmaceuticals Corp. Topical wound therapeutic compositions
CA2312109A1 (en) * 2000-06-23 2001-12-23 Universite De Sherbrooke Use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides

Also Published As

Publication number Publication date
JP2005535674A (ja) 2005-11-24
US20060052309A1 (en) 2006-03-09
EP1556080A1 (en) 2005-07-27
ATE486609T1 (de) 2010-11-15
CA2492331A1 (en) 2004-01-29
JP4630661B2 (ja) 2011-02-09
US20110059896A1 (en) 2011-03-10
EP1556080B1 (en) 2010-11-03
US7700562B2 (en) 2010-04-20
ES2355094T3 (es) 2011-03-22
WO2004009113A1 (en) 2004-01-29
AU2003254473B2 (en) 2008-05-01
DE60334830D1 (de) 2010-12-16
GB0217136D0 (en) 2002-09-04
AU2003254473A1 (en) 2004-02-09
HK1073438A1 (en) 2005-10-07

Similar Documents

Publication Publication Date Title
MY169308A (en) Treatment of tnf? related disorders
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE418336T1 (de) Verwendung von i kappa b-kinase inhibitoren in der schmerztherapie
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
TW200510397A (en) Conjugated complement cascade inhibitors
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
DK1427409T3 (da) Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
DE60231050D1 (de) Verwendung von Totarol zur Behandlung von Pruritus
AU2003301761A8 (en) Method for treating wounds to promote healing
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
ATE486609T1 (de) Furin-hemmer zur behandlung von fibrose und narbenbildung
ATE369880T1 (de) Mediziniscer verband
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE410235T1 (de) Behandlung von ballastwasser
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
MXPA04007007A (es) Uso de inhibidores del intercambiador cloruro/bicarbonato dependiente del sodio para el tratamiento de enfermedades tromboticas e inflamatorias.
WO2007075853A3 (en) Protease compositions for the treatment of damaged tissue
EE200300507A (et) HIV proteaasi inhibiitorite kasutamine rakkude migratsiooni ja/või invasiooni, koe infiltratsiooni ja turse tekkimise blokeerimiseks
ATE390144T1 (de) Behandlung von fibrosen
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors